NewAmsterdam Pharma Company N.V. (NAMSW) — This stock currently has no analyst coverage. No price targets, ratings, or earnings estimates are available. This is common for preferred shares, warrants, OTC-traded securities, and smaller companies that are not followed by Wall Street analysts.
アナリスト予想 一株当たり利益（EPS） $-2.03 および 売上高 $0.03B 来期予想.
一株当たり利益（EPS）実績推移: 2024: 実績 $-2.56 vs 予想 $-2.03 (下回る -26%). 2025: 実績 $-1.75 vs 予想 $-1.67 (下回る -5.1%). アナリスト精度: 87%.
EPS予測 — NAMSW
87%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$2.56
vs Est –$2.03
▼ 20.7% off
2025
Actual –$1.75
vs Est –$1.67
▼ 4.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
売上高予測 — NAMSW
84%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.046B
vs Est $0.034B
▲ 25.9% off
2025
Actual $0.023B
vs Est $0.024B
▼ 6.6% off
Revenue Trend
Revenue has declined over the period shown. Analysts forecast significant revenue growth ahead.
